Statement: One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response.
Primary_evidence: Outcome Measurement:    Proportion of Patients With Confirmed Tumor Response   Confirmed tumor response was defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on 2 consecutive evaluations at least 8 weeks apart.   Time frame: Up to 5 years Results 1:    Arm/Group Title: Treatment (Ziv-afibercept)   Arm/Group Description: Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 21   Measure Type: Number   Unit of Measure: Participants  Confirmed tumor partial response: 1   No Confirmed reponse: 20
Secondary_evidence: Outcome Measurement:    Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)   Percent change from Baseline to Week 13 in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) calculated using ((Week 13 value - Baseline value) / Baseline value ) x 100.   Time frame: Baseline and Week 13 Results 1:    Arm/Group Title: Bisphosphonate IV Q4W   Arm/Group Description: Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion   Overall Number of Participants Analyzed: 38   Mean (Standard Deviation)   Unit of Measure: Percent change  -10.19         (208.84) Results 2:    Arm/Group Title: Denosumab 30 mg Q4W   Arm/Group Description: Denosumab 30 mg by subcutaneous injection every 4 weeks (Q4W)   Overall Number of Participants Analyzed: 40   Mean (Standard Deviation)   Unit of Measure: Percent change  -52.87         (95.14)